AbbVie Inc. Completes $10B Notes Offering to Fund Apogee Acquisition

What Happened

• AbbVie Inc. announced on August 18, 2026 that it completed a registered underwritten offering of senior notes totaling $10.0 billion to help fund its acquisition of Apogee Therapeutics. The offering included a $500 million floating rate issue due 2028 and eight fixed-rate series with maturities from 2028 through 2066 and coupons ranging from 4.500% to 6.100%.
• The notes are unsecured, unsubordinated obligations that rank equally with AbbVie’s other unsecured debt. The offering was made under AbbVie’s Form S-3ASR registration statement and governed by the company’s base Indenture (Nov 8, 2012) as supplemented on August 18, 2026.

Key Details

• Total principal issued: $10.0 billion (nine series: $500M floating due 2028; $1.0B 4.500% due 2028; $1.25B 4.650% due 2030; $1.5B 4.875% due 2031; $1.25B 5.050% due 2033; $1.5B 5.300% due 2036; $1.0B 5.450% due 2038; $1.5B 6.000% due 2056; $500M 6.100% due 2066).
• Use of proceeds: expected to fund a portion of the cash consideration for the Apogee acquisition and related fees and expenses; any remainder for general corporate purposes.
• Redemption provisions: AbbVie may redeem fixed-rate notes at customary make-whole prices before specified “par call” dates and at 100% (plus accrued interest) on/after each par call date. If AbbVie publicly terminates the Apogee deal or notifies the trustee it will not pursue it, AbbVie must special-redeem most shorter-dated series (floating, 2028, 2030, 2031, 2033, 2036, 2038) at 101% of principal (not applicable to the 2056 and 2066 notes).
• Indenture covenants include customary limitations on liens and on certain mergers or transfers; full indenture text is filed as an exhibit.

Why It Matters

• This $10 billion debt raise is a direct financing step for AbbVie’s acquisition of Apogee, reducing the need to use other liquidity sources or equity for the deal consideration. For bond investors, the offering adds new senior unsecured paper across near-term and long-dated maturities with stated coupon rates and typical call features.
• For shareholders and retail investors, the size and terms of the debt issuance affect AbbVie’s capital structure, interest expense profile, and near-term cash requirements—especially since several series carry conditional mandatory redemption if the acquisition is cancelled.